chimeric antigen receptor gene modified T cells

DRUG3 trials

Sponsors

Shanxi Bethune Hospital, Shandong Qilu Cell Therapy Engineering Technology Co., Ltd

Conditions

Acute Lymphocytic LeukemiaB Cell LymphomaCD30+ Peripheral T-cell LymphomaLymphomaLymphoma, B-CellLymphoma,Non-HodgkinRelapsed Refractory Multiple Myeloma

Early Phase 1

CD30 CAR-T in the Treatment of CD30 Positive Lymphoma

Not yet recruitingNCT07048353

Shandong Qilu Cell Therapy Engineering Technology Co., LtdB Cell Lymphoma, CD30+ Peripheral T-cell Lymphoma, Lymphoma

Start: 2025-07-28End: 2029-07-28Target: 15Updated: 2025-07-02

Unknown Phase

A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors

RecruitingNCT06783816

Shanxi Bethune HospitalAcute Lymphocytic Leukemia, Lymphoma,Non-Hodgkin, Relapsed Refractory Multiple Myeloma

Start: 2023-12-01End: 2028-06-01Target: 45Updated: 2025-01-20

CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma

RecruitingNCT06850285

Shanxi Bethune HospitalLymphoma, B-Cell

Start: 2025-09-05End: 2028-06-01Target: 15Updated: 2025-02-27